2H), 7.23-7.16 (m, 1H), 7.14-7.09 (m, 1H), 6.99-6.89 (m, 1H), 2.99-2.87 (m, 2H), 2.78-2.51 (m, 3H), 1.93-1.77 (m, 2H), 1.48-1.19 (m, 2H);

MASS (ESI, Pos.): 459 $(M+H)^+$.

[0382] Example 7(1):

N-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]-5-fluoro-2-methoxybenzamide

[0383]



[0384] The present compound having the following physical properties was obtained in the same procedures as in Reference Example 180 → Example 76 by using, instead of the compound produced in Reference Example 3(1), the compound produced in Reference Example 3 and using, instead of 3-chlorobenzoyl chloride, 5-fluoro-2-methoxybenzoyl chloride (CAS# 704-03-0).

Purity (LC-MS/ELSD): 99.9% (retention time: 0.54 min.);

TLC (Rf): 0.64 (ethyl acetate : methanol = 9:1, NH silica);

NMR (300 MHz, METHANOL-d4): δ 8.84 (s, 1H), 8.09 (s, 1H), 7.81-7.76 (m, 1H), 7.55 (dd, J=2.00, 1.80Hz, 1H), 7.41 (d, J=1.83Hz, 2H), 7.39-7.24 (m, 2H), 4.08 (s, 3H), 3.14-3.02 (m, 2H), 2.76-2.64 (m,

2H), 7.23-7.16 (m, 1H), 7.14-7.09 (m, 1H), 6.99-6.89 (m, 1H), 2.99-2.87 (m, 2H), 2.78-2.51 (m, 3H), 1.93-1.77 (m, 2H), 1.48-1.19 (m, 2H);

MASS (ESI, Pos.): 459 $(M+H)^+$.

[0382] Example 7(1):

N-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]-5-fluoro-2-methoxybenzamide

[0383]



[0384] The present compound having the following physical properties was obtained in the same procedures as in Reference Example 180 → Example 7 by using, instead of the compound produced in Reference Example 3(1), the compound produced in Reference Example 3 and using, instead of 3-chlorobenzoyl chloride, 5-fluoro-2-methoxybenzoyl chloride (CAS# 704-03-0).

Purity (LC-MS/ELSD): 99.9% (retention time: 0.54 min.);

TLC (Rf): 0.64 (ethyl acetate : methanol = 9:1, NH silica);

NMR (300 MHz, METHANOL-d4): δ 8.84 (s, 1H), 8.09 (s, 1H), 7.81-7.76 (m, 1H), 7.55 (dd, J=2.00, 1.80Hz, 1H), 7.41 (d, J=1.83Hz, 2H), 7.39-7.24 (m, 2H), 4.08 (s, 3H), 3.14-3.02 (m, 2H), 2.76-2.64 (m,

[CLAIMS]

[Claim 1] A compound represented by the general formula (I):



(I)

wherein R^1 represents (1) a halogen atom, (2) a cyano group, (3) a C1-4 alkyl, (4) a C1-4 alkoxy or (5) a C3-8 cycloalkyl, wherein the C1-4 alkyl, the C1-4 alkoxy and the C3-8 cycloalkyl may be respectively and independently substituted with 1 to 3 halogen atoms and/or cyano groups; p represents an integer of 0 to 2; when p is 2, a plurality of R^1 may be the same or different; R^2 and R^3 respectively and independently represent a hydrogen atom or a C1-4 alkyl; R^4 represents a hydrogen atom; or R^2 and R^4 together with an atom to which the R^2 and R^4 are attached may form a 5- to 8-membered nitrogen-containing saturated heterocycle; L represents (1) a bond, (2) $-CR^A=CR^B\rightarrow$ or (3) $-C(=O)-NR^D\rightarrow$ (wherein in each group, the arrow indicates the site of binding to the pyridine ring); R^A, R^B and R^D respectively and independently represent a hydrogen atom or a C1-4 alkyl; X^1 and X^2 respectively and independently represent a halogen atom;

a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing.

[Claim 2] The compound according to claim 1, represented by the general formula (I-1):



(I-1)

wherein L^1 represents (1) $-CR^A=CR^B\rightarrow$ or (2) $-C(=O)-NR^D\rightarrow$ (wherein in each group, the arrow indicates the site of binding to the pyridine ring); and other symbols have the same meanings as described in claim 1,

a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing.

[Claim 3] The compound according to claim 1, represented by the general formula (I-4):



(I-4)

wherein R^{24} represents a hydrogen atom or a C1-4 alkyl; and other symbols have the same meanings as described in claim 1,
a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing.

[Claim 4] The compound according to claim 1, which is selected from the group consisting of the following compounds:

(1)
N-[4-(4-amino-1-piperidinyl)-5-(3-chloro-5-fluorophenyl)-3-pyridinyl]-3-chlorobenzamide;

(2)
1-{3-(3-chloro-5-fluorophenyl)-5-[(E)-2-(3-chlorophenyl)vinyl]-4-pyridinyl}-4-piperidineamine;

(3)
3-{(E)-2-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]vinyl}benzonitrile;

(4)
(4aS,8aS)-6-{3-(3,5-dichlorophenyl)-5-[(E)-2-(3-fluorophenyl)vinyl]-4-pyridinyl}octahydro-1H-pyrido[3,4-b][1,4]oxazine;

(5)
1-{3-(3,5-dichlorophenyl)-5-[(1E)-2-(3-fluorophenyl)-1-propen-1-yl]-4-pyridinyl}-4-piperidineamine;

(6)
3-[(E)-2-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}vinyl]benzonitrile;

(7)
1-{3-(3,5-dichlorophenyl)-5-[(1E)-2-(3-fluorophenyl)-1-propen-

1-yl]-4-pyridinyl}-N-ethyl-4-piperidineamine;

(8)

3-{(1E)-1-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]-1-propen-2-yl}benzonitrile;

(9)

3-[(1E)-1-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}-1-propen-2-yl]benzonitrile;

(10)

N-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]-5-fluoro-2-methoxybenzamide;

(11)

1-(4-{5-(3,5-dichlorophenyl)-4-[(4aS,8aS)-octahydro-6H-pyrido[3,4-b][1,4]oxazin-6-yl]-3-pyridinyl}phenyl)cyclopropanecarbonitrile;

(12)

1-{3-(3-chloro-5-fluorophenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-4-piperidineamine;

(13)

1-{3-(3,5-dichlorophenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-4-piperidineamine;

(14)

1-{3-(3-chloro-5-fluorophenyl)-5-[4-(difluoromethoxy)phenyl]-4-pyridinyl}-4-piperidineamine;

(15)

1-{4-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]phenyl}cyclopropanecarbonitrile;

(16)

1-{3-(3,5-dichlorophenyl)-5-[4-(difluoromethoxy)phenyl]-4-pyridinyl}-4-piperidineamine;

(17)

1-(4-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}phenyl)cyclopropanecarbonitrile;

(18)

2-{4-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]phenyl}-2-methylpropanenitrile;

(19)

2-(4-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}phenyl)-2-methylpropanenitrile;

(20)

1-{3-(3,5-dichlorophenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-N-ethyl-4-piperidineamine; and

(21)

1-{3-(3,5-dichlorophenyl)-5-[4-(difluoromethoxy)phenyl]-4-pyridinyl}-N-ethyl-4-piperidineamine,

a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing.

[Claim 5] The compound according to claim 2, which is selected from the group consisting of the following compounds:

(1)

N-[4-(4-amino-1-piperidinyl)-5-(3-chloro-5-fluorophenyl)-3-pyridinyl]-3-chlorobenzamide;

(2)

1-{3-(3-chloro-5-fluorophenyl)-5-[(E)-2-(3-chlorophenyl)vinyl]-4-pyridinyl}-4-piperidineamine;

(3)

3-{(E)-2-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]vinyl}benzonitrile;

(4)

(4aS,8aS)-6-{3-(3,5-dichlorophenyl)-5-[(E)-2-(3-fluorophenyl)vinyl]-4-pyridinyl}octahydro-1H-pyrido[3,4-b][1,4]oxazine;

(5)

1-{3-(3,5-dichlorophenyl)-5-[(1E)-2-(3-fluorophenyl)-1-propen-1-yl]-4-pyridinyl}-4-piperidineamine;

(6)

3-[(E)-2-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}vinyl]benzonitrile;

(7)

1-{3-(3,5-dichlorophenyl)-5-[(1E)-2-(3-fluorophenyl)-1-propen-1-yl]-4-pyridinyl}-N-ethyl-4-piperidineamine;

(8)

3-{(1E)-1-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]-1-propen-2-yl}benzonitrile;

(9)

3-[(1E)-1-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}-1-propen-2-yl]benzonitrile; and

(10)

N-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]-5-fluoro-2-methoxybenzamide,

a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing.

[Claim 6] The compound according to claim 3, which is selected from the group consisting of the following compounds:

(1)

1-{3-(3-chloro-5-fluorophenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-4-piperidineamine;

(2)

1-{3-(3,5-dichlorophenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-4-piperidineamine;

(3)

1-{3-(3-chloro-5-fluorophenyl)-5-[4-(difluoromethoxy)phenyl]-4-pyridinyl}-4-piperidineamine;

(4)

1-{4-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]phenyl}cyclopropanecarbonitrile;

(5)

1-{3-(3,5-dichlorophenyl)-5-[4-(difluoromethoxy)phenyl]-4-pyridinyl}-4-piperidineamine;

(6)

1-(4-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}phenyl)cyclopropanecarbonitrile;

(7)

2-{4-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]phenyl}-2-methylpropanenitrile;

(8)

2-(4-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}phenyl)-2-methylpropanenitrile;

(9)

1-{3-(3,5-dichlorophenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-N-ethyl-4-piperidineamine; and

(10)

1-{3-(3,5-dichlorophenyl)-5-[4-(difluoromethoxy)phenyl]-4-pyridinyl}-N-ethyl-4-piperidineamine,

a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing.

[Claim 7] A pharmaceutical composition comprising the compound according to claim 1, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing and a pharmaceutically acceptable carrier.

[Claim 8] The pharmaceutical composition according to claim 7, which is a prophylactic and/or therapeutic agent for a somatostatin-related disease.

[Claim 9] The pharmaceutical composition according to claim 8, wherein the somatostatin-related disease is acromegaly or a gastrointestinal symptom accompanying gastrointestinal obstruction.

[Claim 10] A medicament comprising the compound according to claim 1, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing in combination with at least one drug selected from the group consisting of pegvisomant, bromocriptine and cabergoline.

[Claim 11] A medicament comprising the compound according to claim 1, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing in combination with at least one drug selected from the group consisting of prochlorperazine, levomepromazine, risperidone, metoclopramide, domperidone, diphenhydramine, chlorpheniramine, dimenhydrinate, promethazine, diprophylline, famotidine, cimetidine, scopolamine, tropisetron, granisetron, ondansetron, azasetron, ramosetron, indisetron, palonosetron, cisapride, mosapride, dexamethasone, betamethasone, prednisolone, olanzapine, quetiapine, perospirone, methylnaltrexone and morphine.

[Claim 12] A method for prophylaxis and/or therapy of a somatostatin-related disease, comprising administering to a mammal an effective amount of the compound according to claim 1, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing.

[Claim 13] The compound according to claim 1, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing for prophylaxis and/or therapy of a somatostatin-related disease.

[Claim 14] Use of the compound according to claim 1, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing for producing a prophylactic and/or therapeutic agent for a somatostatin-related disease.

[CLAIMS]

[Claim 1] A compound represented by the general formula (I):



(I)

wherein R^1 represents (1) a halogen atom, (2) a cyano group, (3) a C1-4 alkyl, (4) a C1-4 alkoxy or (5) a C3-8 cycloalkyl, wherein the C1-4 alkyl, the C1-4 alkoxy and the C3-8 cycloalkyl may be respectively and independently substituted with 1 to 3 halogen atoms and/or cyano groups; p represents an integer of 0 to 2; when p is 2, a plurality of R^1 may be the same or different; R^2 and R^3 respectively and independently represent a hydrogen atom or a C1-4 alkyl; R^4 represents a hydrogen atom; or R^2 and R^4 together with an atom to which the R^2 and R^4 are attached may form a 5- to 8-membered nitrogen-containing saturated heterocycle; L represents (1) a bond, (2) $-CR^A=CR^B\rightarrow$ or (3) $-C(=O)-NR^D\rightarrow$ (wherein in each group, the arrow indicates the site of binding to the pyridine ring); R^A, R^B and R^D respectively and independently represent a hydrogen atom or a C1-4 alkyl; X^1 and X^2 respectively and independently represent a halogen atom;

a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing.

[Claim 2] The compound according to claim 1, represented by the general formula (I-1):



(I-1)

wherein L^1 represents (1) $-CR^A=CR^B\rightarrow$ or (2) $-C(=O)-NR^D\rightarrow$ (wherein in each group, the arrow indicates the site of binding to the pyridine ring); and other symbols have the same meanings as described in claim 1,

a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing.

[Claim 3] The compound according to claim 1, represented by the general formula (I-4):



(I-4)

wherein R^{24} represents a hydrogen atom or a C1-4 alkyl; and other symbols have the same meanings as described in claim 1,
a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing.

[Claim 4] The compound according to claim 1, which is selected from the group consisting of the following compounds:

(1)
N-[4-(4-amino-1-piperidinyl)-5-(3-chloro-5-fluorophenyl)-3-pyridinyl]-3-chlorobenzamide;

(2)
1-{3-(3-chloro-5-fluorophenyl)-5-[(E)-2-(3-chlorophenyl)vinyl]-4-pyridinyl}-4-piperidineamine;

(3)
3-{(E)-2-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]vinyl}benzonitrile;

(4)
(4aS,8aS)-6-{3-(3,5-dichlorophenyl)-5-[(E)-2-(3-fluorophenyl)vinyl]-4-pyridinyl}octahydro-1H-pyrido[3,4-b][1,4]oxazine;

(5)
1-{3-(3,5-dichlorophenyl)-5-[(1E)-2-(3-fluorophenyl)-1-propen-1-yl]-4-pyridinyl}-4-piperidineamine;

(6)
3-[(E)-2-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}vinyl]benzonitrile;

(7)
1-{3-(3,5-dichlorophenyl)-5-[(1E)-2-(3-fluorophenyl)-1-propen-

1-yl]-4-pyridinyl}-N-ethyl-4-piperidineamine;

(8)

3-{(1E)-1-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]-1-propen-2-yl}benzonitrile;

(9)

3-[(1E)-1-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}-1-propen-2-yl]benzonitrile;

(10)

N-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]-5-fluoro-2-methoxybenzamide;

(11)

1-(4-{5-(3,5-dichlorophenyl)-4-[(4aS,8aS)-octahydro-6H-pyrido[3,4-b][1,4]oxazin-6-yl]-3-pyridinyl}phenyl)cyclopropanecarbonitrile;

(12)

1-{3-(3-chloro-5-fluorophenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-4-piperidineamine;

(13)

1-{3-(3,5-dichlorophenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-4-piperidineamine;

(14)

1-{3-(3-chloro-5-fluorophenyl)-5-[4-(difluoromethoxy)phenyl]-4-pyridinyl}-4-piperidineamine;

(15)

1-{4-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]phenyl}cyclopropanecarbonitrile;

(16)

1-{3-(3,5-dichlorophenyl)-5-[4-(difluoromethoxy)phenyl]-4-pyridinyl}-4-piperidineamine;

(17)

1-(4-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}phenyl)cyclopropanecarbonitrile;

(18)

2-{4-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]phenyl}-2-methylpropanenitrile;

(19)

2-(4-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}phenyl)-2-methylpropanenitrile;

(20)

1-{3-(3,5-dichlorophenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-N-ethyl-4-piperidineamine; and

(21)

1-{3-(3,5-dichlorophenyl)-5-[4-(difluoromethoxy)phenyl]-4-pyridinyl}-N-ethyl-4-piperidineamine,

a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing.

[Claim 5] The compound according to claim 2, which is selected from the group consisting of the following compounds:

(1)

N-[4-(4-amino-1-piperidinyl)-5-(3-chloro-5-fluorophenyl)-3-pyridinyl]-3-chlorobenzamide;

(2)

1-{3-(3-chloro-5-fluorophenyl)-5-[(E)-2-(3-chlorophenyl)vinyl]-4-pyridinyl}-4-piperidineamine;

(3)

3-{(E)-2-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]vinyl}benzonitrile;

(4)

(4aS,8aS)-6-{3-(3,5-dichlorophenyl)-5-[(E)-2-(3-fluorophenyl)vinyl]-4-pyridinyl}octahydro-1H-pyrido[3,4-b][1,4]oxazine;

(5)

1-{3-(3,5-dichlorophenyl)-5-[(1E)-2-(3-fluorophenyl)-1-propen-1-yl]-4-pyridinyl}-4-piperidineamine;

(6)

3-[(E)-2-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}vinyl]benzonitrile;

(7)

1-{3-(3,5-dichlorophenyl)-5-[(1E)-2-(3-fluorophenyl)-1-propen-1-yl]-4-pyridinyl}-N-ethyl-4-piperidineamine;

(8)

3-{(1E)-1-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]-1-propen-2-yl}benzonitrile;

(9)

3-[(1E)-1-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}-1-propen-2-yl]benzonitrile; and

(10)

N-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]-5-fluoro-2-methoxybenzamide,

a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing.

[Claim 6] The compound according to claim 3, which is selected from the group consisting of the following compounds:

(1)

1-{3-(3-chloro-5-fluorophenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-4-piperidineamine;

(2)

1-{3-(3,5-dichlorophenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-4-piperidineamine;

(3)

1-{3-(3-chloro-5-fluorophenyl)-5-[4-(difluoromethoxy)phenyl]-4-pyridinyl}-4-piperidineamine;

(4)

1-{4-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]phenyl}cyclopropanecarbonitrile;

(5)

1-{3-(3,5-dichlorophenyl)-5-[4-(difluoromethoxy)phenyl]-4-pyridinyl}-4-piperidineamine;

(6)

1-(4-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}phenyl)cyclopropanecarbonitrile;

(7)

2-{4-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]phenyl}-2-methylpropanenitrile;

(8)

2-(4-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}phenyl)-2-methylpropanenitrile;

(9)

1-{3-(3,5-dichlorophenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-N-ethyl-4-piperidineamine; and

(10)

1-{3-(3,5-dichlorophenyl)-5-[4-(difluoromethoxy)phenyl]-4-pyridinyl}-N-ethyl-4-piperidineamine,

a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing.

[Claim 7] A pharmaceutical composition comprising the compound according to claim 1, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing and a pharmaceutically acceptable carrier.

[Claim 8] The pharmaceutical composition according to claim 7, which is a prophylactic and/or therapeutic agent for a somatostatin-related disease.

[Claim 9] The pharmaceutical composition according to claim 8, wherein the somatostatin-related disease is acromegaly or a gastrointestinal symptom accompanying gastrointestinal obstruction.

[Claim 10] A medicament comprising the compound according to claim 1, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing in combination with at least one drug selected from the group consisting of pegvisomant, bromocriptine and cabergoline.

[Claim 11] A medicament comprising the compound according to claim 1, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing in combination with at least one drug selected from the group consisting of prochlorperazine, levomepromazine, risperidone, metoclopramide, domperidone, diphenhydramine, chlorpheniramine, dimenhydrinate, promethazine, diprophylline, famotidine, cimetidine, scopolamine, tropisetron, granisetron, ondansetron, azasetron, ramosetron, indisetron, palonosetron, cisapride, mosapride, dexamethasone, betamethasone, prednisolone, olanzapine, quetiapine, perospirone, methylnaltrexone and morphine.

[Claim 12] The compound according to claim 1, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing for prophylaxis and/or therapy of a somatostatin-related disease.

[Claim 13] Use of the compound according to claim 1, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing for producing a prophylactic and/or therapeutic agent for a somatostatin-related disease.

SEQUENCE LISTING

<110> ONO PHARMACEUTICAL CO., LTD.

<120> NEW COMPOUNDS HAVING SSTR2 AGONISTIC ACTIVITY AND PHARMACEUTICAL USE THEREOF

<130> P14-125

<150> JP 2013-205027
<151> 2013-09-30

<150> JP 2013-268902
<151> 2013-12-26

<160> 2

<170> PatentIn Ver. 3.5.1

<210> 1
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward primer hSSTR2_F1_XhoI

<400> 1
caccctcgag gacatggcgg atgagccact caat 34

<210> 2
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse primer hSSTR2_R1_EcoRI

<400> 2
ccttgaattc gatactggtt tggaggtctc catt 34

SEQUENCE LISTING

<110> ONO PHARMACEUTICAL CO., LTD.

<120> COMPOUND HAVING SOMATOSTATIN RECEPTOR AGONISTIC ACTIVITY AND PHARMACEUTICAL USE THEREOF

<130> P14-125

<150> JP 2013-205027
<151> 2013-09-30

<150> JP 2013-268902
<151> 2013-12-26

<160> 2

<170> PatentIn Ver. 3.5.1

<210> 1
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward primer hSSTR2_F1_XhoI

<400> 1
caccctcgag gacatggcgg atgagccact caat 34

<210> 2
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse primer hSSTR2_R1_EcoRI

<400> 2
ccttgaattc gatactggtt tggaggtctc catt 34